XTL cuts staff by 25%

The layoffs, 13 in total, follow an announcement in June to reduce staff by 20 and implement salary cuts in order to extend the reach of the company's available funds.

By AVI KRAWITZ
December 19, 2005 08:08
xtl logo 88

xtl logo 88. (photo credit: )

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For a symbolic $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Don't show it again

XTL Biopharmaceuticals Ltd. said over the weekend it was reducing its Rehovot-based work force by a further 25 percent, as part of a plan to refocus its resources on the development of two of its drugs for hepatitis C - XTL-6865 and XTL-2125. The layoffs, 13 in total, follow an announcement in June to reduce staff by 20 and implement salary cuts in order to extend the reach of the company's available funds. Last week the company said it was in talks to hire a new CEO. Its CEO of 10 years, Martin Becker, resigned from the position a year ago and his replacement, Elkan Gamzu, was ousted, along with other directors, in February by shareholder vote.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS